MINK THERAPEUTICS

MiNK Therapeutics is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies for cancer and other immune-mediated diseases. The lead product is an off-the-shelf, cell therapy based on a targeted platform of invariant natural killer T (iNKT) cells. iNKTs have a dual-mechanism of action with an internal targeting and homing device (iTCR) that modulates both arms of immunity, innate and adaptive. iNKTs combine the killing features of natural killer (NK) cells with the durable memory response of T cells. iNKT cells have been demonstrated to be highly effective in treating solid tumor cancers in their native form and MiNK has demonstrated that these cells can be further engineered or edited for super-targeting... MiNK's lead product candidate AGENT-797 is in multiple Phase 1 clinical trials with clinical and preclinical readouts anticipated later this year. Our research team is focused on developing potential first-or best-in-class..

Also known as: MiNK, MiNK Therapeutics, Inc.

Primary location: New York United States